Assessment of Elemental Impurities Level After Multiple Administration of DWJ1230 or DWB2001 in Subjects With Functional Diarrhea or Irritable Bowel Syndrome With Predominant Diarrhea.

Inclusion Criteria: * Subjects with chronic functional Diarrhea. (included Irritable Bowel Syndrome with perdominant diarrhea(IBS-D)). * Male or Female subjects aged between 19 and 60 years at screening. * Body Mass Index(BMI) between 18 and 27kg/m2 in male, 17 and 26kg/m2 in female. ※ BMI (kg/m2) = body weight (kg)/\[height (m)\]2 * Subjects who voluntarily decided to participate in the study and provided written consent to follow precautions after receiving a sufficient explanation on this study and fully understanding the information. Exclusion Criteria: * No history or clinically significant symptoms or severe disease, including cardiac, neurological, pulmonary, hepatic, biliary, gastrointestinal, endocrinologic, or renal disorders, or cancer. * Identified or strongly suspected organic cause to diarrhea. * Celiac disease or Intestinal malabsorption, Unspecified intestinal malabsorption. * History of any serious adverse reaction or adverse event or hypersensitivity to any component of investigational product. * Constipation, Iron deficiency anaemia, Hypocalcaemia, Osteoporosis. * Known domestic, leisure or professional exposure to elemental impurities. * Women who are breastfeeding or are planning to become pregnant during the study. * Positive pregnancy test at screening. * Presence of clinically significant physical, laboratory, vital signs, or ECG findings. * Blood lead level \> 3.3 μg/dL(=33.0 μg/L) at screening. * galactose intolerance, fructose intolerance, Lapp lactase deficiency, sucurase-isomaltase deficiency, glucose-galactose malabsorption. * Receipt of any investigational agent or study drug within 4 weeks prior to screening. * Patients with history of alcohol or drug abuse. * Subjects who donated whole blood within 2 months, donated blood components within 1 month. * Subjects who have participated and taken investigational drug within 1 month prior to study drug administration. * Subjects who the investigator considers inappropriate for the study due to other reasons.